BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33518465)

  • 1. Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
    Sørup S; Englund H; Laake I; Nieminen H; Gehrt L; Feiring B; Trogstad L; Roth A; Benn CS
    Vaccine; 2022 Mar; 40(11):1583-1593. PubMed ID: 33518465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Gehrt L; Englund H; Laake I; Nieminen H; Möller S; Feiring B; Lahdenkari M; Trogstad L; Benn CS; Sørup S
    Vaccine; 2024 Apr; 42(12):2955-2965. PubMed ID: 38508926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revaccination With Measles-Mumps-Rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study.
    Sørup S; Jensen AKG; Aaby P; Benn CS
    Clin Infect Dis; 2019 Jan; 68(2):282-290. PubMed ID: 29846533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis.
    Wang M; Yuan Q; Deng PF; Fei Y; Zhang H; Zhou F; Chen WJ; Cao Q; Chen J; Gao YJ
    World J Pediatr; 2023 Nov; 19(11):1062-1070. PubMed ID: 37087716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
    Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
    JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact.
    Sørup S; Benn CS; Stensballe LG; Aaby P; Ravn H
    Vaccine; 2015 Jan; 33(1):237-45. PubMed ID: 25446818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to co-administration of measles, mumps, and rubella (MMR), and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina.
    Vizzotti C; Harris JB; Aquino A; Rancaño C; Biscayart C; Bonaventura R; Pontoriero A; Baumeister E; Freire MC; Magariños M; Duarte B; Grant G; Reef S; Laven J; Wannemuehler KA; Alvarez AMR; Staples JE
    BMC Infect Dis; 2023 Mar; 23(1):165. PubMed ID: 36932346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.
    Saffar H; Khalifeloo M; Saffar MJ; Abdollahi A; Parsaei MR; Ghorbani GR; Salarvand S; Aarabi M
    BMC Infect Dis; 2021 Mar; 21(1):305. PubMed ID: 33765968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan.
    Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM
    J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.